Advos

Alpha Cognition Raises $35 Million in Oversubscribed Offering to Accelerate Neurodegenerative Disease Treatment

October 3rd, 2025 5:45 PM
By: Advos Staff Reporter

Alpha Cognition's successful $35 million public offering will accelerate commercialization of ZUNVEYL for Alzheimer's treatment and expand development of therapies for neurodegenerative diseases with significant unmet medical needs.

Alpha Cognition Raises $35 Million in Oversubscribed Offering to Accelerate Neurodegenerative Disease Treatment

Alpha Cognition Inc. (NASDAQ: ACOG) has priced an oversubscribed underwritten public offering of 5.6 million common shares at $6.25 per share, generating approximately $35 million in gross proceeds before expenses. The biopharmaceutical company, focused on neurodegenerative disease treatments, will use the net proceeds to accelerate commercialization efforts for ZUNVEYL(R) (Benzgalantamine), including sales expansion, marketing initiatives, payer coverage development, and reimbursement infrastructure.

This funding round represents significant investor confidence in Alpha Cognition's pipeline and comes at a critical time for neurodegenerative disease treatment development. CEO Michael McFadden stated that the capital infusion will help maximize near-term adoption of their treatments while establishing the foundation for long-term growth. The offering's oversubscribed status indicates strong market interest in innovative approaches to Alzheimer's disease and related conditions.

The company's lead product, ZUNVEYL, represents a new generation acetylcholinesterase inhibitor for Alzheimer's disease treatment with expected minimal gastrointestinal side effects. What distinguishes ZUNVEYL from existing treatments like donepezil and rivastigmine is its active metabolite's binding to neuronal nicotinic receptors, particularly the alpha-7 subtype, which has demonstrated positive effects on cognition. This differentiation could potentially offer improved treatment options for the millions affected by Alzheimer's disease worldwide.

Beyond ZUNVEYL, Alpha Cognition is developing ALPHA-1062 in combination with memantine for moderate to severe Alzheimer's dementia and as an intranasal formulation for Cognitive Impairment with mild Traumatic Brain Injury (mTBI). These development areas address significant unmet medical needs, as there are currently no approved treatment options for Cognitive Impairment with mTBI. The company's broader pipeline targeting multiple neurodegenerative conditions positions it to potentially impact various patient populations facing limited therapeutic options.

Titan Partners Group, a division of American Capital Partners, acted as sole bookrunner for the offering and was granted a 30-day option to purchase up to an additional 840,000 shares to cover over-allotments. This financial backing comes as the global Alzheimer's disease therapeutics market continues to grow, driven by increasing prevalence and the urgent need for more effective treatments with fewer side effects. For additional information about Alpha Cognition's developments, visit https://www.alphacognition.com/.

The successful funding round highlights the ongoing investor interest in biotechnology companies addressing neurodegenerative diseases, particularly those with differentiated mechanisms of action and multiple development pathways. As the global population ages and neurodegenerative conditions become more prevalent, treatments like those being developed by Alpha Cognition could play an increasingly important role in managing these debilitating conditions and improving patient quality of life.

Source Statement

This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,

blockchain registration record for the source press release.
Back To Top